| Subject: | FDA Approves Safety Labeling Changes to Commonly Used Drugs |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 31 Aug 2005 - 10:00 am |
| The FDA has approved safety-labeling changes to commonly used medications. Changes have been made to the CONTRAINDICATIONS, BOXED WARNING, WARNINGS, PRECAUTIONS, or ADVERSE REACTIONS. For detailed information on individual drugs, click on the links or documents below.
3% and 5% Sodium Chloride Injection, USP -5% Dextrose and Electrolyte No. 48 Injection -5% Dextrose and Electrolyte No. 75 Injection -Accolate (zafirlukast) Tablets -Activella (estradiol/norethindrone acetate... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
Related MCN Products:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
